Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 4/2023

11-02-2023 | Obesity | Original Contributions

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study

Authors: Anders Boisen Jensen, Frida Renström, Stefan Aczél, Patrick Folie, Magdalena Biraima-Steinemann, Felix Beuschlein, Stefan Bilz

Published in: Obesity Surgery | Issue 4/2023

Login to get access

Abstract

Purpose

Weight regain after bariatric surgery occurs in up to a third of patients and reduces treatment-associated health benefits. The efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RA) for treatment of type 2 diabetes mellitus and obesity is well established, but their role in the treatment of weight regain after bariatric surgery remains to be defined.

Materials and Methods

This was a single centre retrospective observational study conducted at a Swiss bariatric reference centre. Patients with 6 months of treatment with GLP1-RA, up until November 2021, due to weight regain after bariatric surgery were identified. Data on body weight and relevant clinical parameters were collected before and after 6 months of treatment with GLP1-RA. Data are presented as median (interquartile range).

Results

Fifty patients (82% female) were included. Before GLP1-RA treatment (liraglutide, n=29; semaglutide, n=21), weight and BMI were 90.5 kg (83.4, 107.9) and 34.0 kg/m2 (31.7, 38.7), respectively, with a post-bariatric weight regain of 15.1% (10.6, 22.8) of total body weight and 4.6 kg/m2 (3.3, 6.2). After 6 months of GLP1-RA treatment, a reduction in weight and BMI of 8.8% (5.2, 11.4) of total body weight and 2.9 kg/m2 (1.8, 4.0) was observed (P value <0.0001), corresponding to 67.4% (40.4, 92.2) of the weight regain. No serious adverse events were reported.

Conclusion

For patients experiencing weight regain after bariatric surgery, two-thirds of the weight regain can be safely lost with GLP1-RA, providing clinicians with a therapeutic option for this clinical challenge, and highlights the need for a large-scale randomized clinical trial.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
Syn NL, Cummings DE, Wang LZ, Lin DJ, Zhao JJ, Loh M, Koh ZJ, Chew CA, Loo YE, Tai BC, Kim G, So JBY, Kaplan LM, Dixon JB, Shabbir A. Association of metabolic–bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. The Lancet. 2021;397(10287):1830–41.CrossRef
2.
Voorwinde V, Steenhuis IHM, Janssen IMC, Monpellier VM, van Stralen MM. Definitions of long-term weight regain and their associations with clinical outcomes. Obes Surg. 2020;30(2):527–36.CrossRefPubMed
3.
Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879.CrossRefPubMed
4.
Cambi MPC, Baretta GAP, Magro DDO, Boguszewski CL, Ribeiro IB, Jirapinyo P, de Moura DTH. Multidisciplinary approach for weight regain—how to manage this challenging condition: an expert review. Obes Surg. 2021;31(3):1290–303.CrossRefPubMed
5.
Shukla AP, He D, Saunders KH, Andrew C, Aronne LJ. Current concepts in management of weight regain following bariatric surgery. Expert Rev Endocrinol Metab. 2018;13(2):67–76.CrossRefPubMed
6.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.CrossRefPubMedPubMedCentral
7.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.CrossRefPubMed
8.
Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85.CrossRefPubMed
9.
Rothkopf MM, Bilof ML, Haverstick LP, Nusbaum MJ. Synergistic weight loss and diabetes resolution with exenatide administration after laparoscopic gastric banding. Surg Obes Relat Dis. 2009;5(1):128–31.CrossRefPubMed
10.
Pajecki D, Halpern A, Cercato C, Mancini M, de Cleva R, Santo MA. Tratamento de curto prazo com liraglutide no reganho de peso após cirurgia bariátrica. Rev Colégio Bras Cir. 2013;40(3):191–5.CrossRef
11.
Gorgojo-Martínez JJ, Feo-Ortega G, Serrano-Moreno C. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surg Obes Relat Dis. 2016;12(10):1856–63.CrossRefPubMed
12.
Creange C, Lin E, Ren-Fielding C, Lofton H. Use of liraglutide for weight loss in patients with prior bariatric surgery. Surg Obes Relat Dis. 2016;12(7):S157.
13.
Rye P, Modi R, Cawsey S, Sharma AM. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28(11):3553–8.CrossRefPubMed
14.
Wharton S, Kuk JL, Luszczynski M, et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery. Clin Obes. 2019;9(4):e12323.
15.
Suliman M, Buckley A, Al Tikriti A, Tan T, le Roux CW, Lessan N, Barakat M. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients. Diabetes Obes Metab. 2019;21(6):1498–501.CrossRefPubMed
16.
Bretault M, Carette C, Zaharia R, Vychnevskaia K, Bouillot JL, Czernichow S, Raffin-Sanson ML. Liraglutide 3 mg as a weight-loss strategy after failed bariatric surgery in a patient with hypothalamic obesity following craniopharyngioma. Diabetes Metab. 2020;46(6):514–5.CrossRefPubMed
17.
Rubio MA, Ramos-Leví AM. Initial experience with alternate-day liraglutide for weight regain following bariatric surgery. Obes Surg. 2021;31(9):4216–8.CrossRefPubMed
18.
Horber FF, Steffen R. Reversal of long-term weight regain after Roux-en-Y gastric bypass using liraglutide or surgical revision. A Prospective Study. Obes Surg. 2021;31(1):93–100.
19.
Elhag W, El Ansari W. Effectiveness and safety of liraglutide in managing inadequate weight loss and weight regain after primary and revisional bariatric surgery: anthropometric and cardiometabolic outcomes. Obes Surg. 2022;32(4):1005–15.CrossRefPubMed
20.
Dharmaratnam VM, Lim E, Eng A, et al. Revisional surgery or pharmacotherapy for insufficient weight loss and weight regain after primary bariatric procedure: a descriptive study. Obes Surg. 2022;32(10):3298–3304.
21.
Miras AD, Pérez-Pevida B, Aldhwayan M, Kamocka A, McGlone ER, Al-Najim W, Chahal H, Batterham RL, McGowan B, Khan O, Greener V, Ahmed AR, Petrie A, Scholtz S, Bloom SR, Tan TM. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(7):549–59.CrossRefPubMed
22.
23.
Redmond IP, Shukla AP, Aronne LJ. Use of weight loss medications in patients after bariatric surgery. Curr Obes Rep. 2021;10(2):81–9.CrossRefPubMed
24.
Lautenbach A, Wernecke M, Huber TB, et al. The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery—a retrospective analysis. Obes Surg. 2022;32(10):3280–3288.
25.
O’Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet. 2018;392(10148):637–49.CrossRef
26.
Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet. 2019;394(10192):39–50.CrossRef
27.
Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT, STEP 8 Investigators, Arauz-Pacheco C, Cannon K, Downey HJ, Fitz-Patrick D, Geohas J, Gerety G, Gilbert J, Hollander P, Klein E, Laufer K, O’Donnell P, Rosenblit P, Toth P. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138.
28.
Fujioka K, O’Neil PM, Davies M, Greenway F, C.W. Lau D, Claudius B, Skjøth TV, Bjørn Jensen C, P.H. Wilding J. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity. 2016;4(11):2278–88.CrossRef
29.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.CrossRefPubMed
30.
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Andreasen AH, Jensen CB, DeFronzo RA, for the NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687.CrossRef
31.
Sorli C, Harashima S, ichi, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–60.CrossRefPubMed
32.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.CrossRefPubMed
33.
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021;397(10278):971–84.CrossRef
34.
35.
Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–9.CrossRefPubMed
36.
Lampropoulos C, Alexandrides T, Tsochatzis S, Kehagias D, Kehagias I. Are the changes in gastrointestinal hormone secretion necessary for the success of bariatric surgery? A Critical Review of the Literature. Obes Surg. 2021;31(10):4575–84.CrossRefPubMed
37.
Santo MA, Riccioppo D, Pajecki D, Kawamoto F, de Cleva R, Antonangelo L, Marçal L, Cecconello I. Weight regain after gastric bypass: influence of gut hormones. Obes Surg. 2016;26(5):919–25.CrossRefPubMed
38.
Nedelcu M, Khwaja HA, Rogula TG. Weight regain after bariatric surgery—how should it be defined? Surg Obes Relat Dis. 2016;12(5):1129–30.CrossRefPubMed
39.
Lauti M, Kularatna M, Hill AG, MacCormick AD. Weight regain following sleeve gastrectomy—a systematic review. Obes Surg. 2016;26(6):1326–34.CrossRefPubMed
Metadata
Title
Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study
Authors
Anders Boisen Jensen
Frida Renström
Stefan Aczél
Patrick Folie
Magdalena Biraima-Steinemann
Felix Beuschlein
Stefan Bilz
Publication date
11-02-2023
Publisher
Springer US
Published in
Obesity Surgery / Issue 4/2023
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-023-06484-8

Other articles of this Issue 4/2023

Obesity Surgery 4/2023 Go to the issue

Multimedia Article

A Video-Based Review of Important Technical Concepts in the Nissen-Sleeve Gastrectomy

Brief Communication

Ethical Challenges in Delivering Surgical Innovation: Laparoscopic Bariatric-Metabolic Surgery and Sentinel Node Biopsy for Melanoma: an Australian Perspective

Original Contributions

Characterizing the Course of Loss of Control Eating and Prognostic Factors Following Bariatric Surgery: an Exploratory Analysis

Multimedia Article

From Our One Anastomosis Gastric Bypass (OAGB) Experience to Establishing Single Anastomosis Sleeve Ileal (SASI) Bypass Procedure: A Single-Center Report

Letter to the Editor

A View from a Different Standing Point: Reply to the Letter to the Editor Titled “Is It Acceptable to Call a Position Statement Questionable to Raise More Doubt About an Already Debatable Procedure?”

Original Contributions

Establishing Methods of Defect Closure in Roux-en-Y Gastric Bypass: an International Survey